Please feel free to forward to fellow researchers and share news of our journal | Dear Colleague, We are delighted to announce the publication of Volume 4, Issue 4 of our Kidney Cancer journal. This issue includes one article commentary looking at immunotherapy-based doublets that join a growing list of highly active combination regimens in the frontline mRCC setting, three research articles, a systematic review, and a new Clinical Trials Corner contribution. View all the open access content via the links below. | Call for Papers As a member of our community, we would like to invite you to submit your own research articles to the journal, which offers contributing authors many benefits: • First class Editorial Board
• Rigorous peer review and speedy manuscript processing
• Rapid online publication (pre-press) on acceptance
• The first volumes of the journal freely available to all readers
• Articles accepted this year will be published open access with no article processing fee Submit your manuscript online via msTracker
View detailed Instructions to Authors
Aims and Scope Kidney Cancer is an international, multidisciplinary journal that provides an invaluable and indispensable platform for the many collaborative, transdisciplinary, and translational efforts to help treat and finally cure this malignancy. Best wishes, Primo N. Lara Jr, MD
UC Davis Comprehensive Cancer Center
Sacramento, CA, USA
Email: kca@iospress.com Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands
Email: kca@iospress.com Editors-in-Chief
Sign up now for Kidney Cancer news
Join the conversation at: twitter.com/KCA_Journal | All articles are freely available online for all to read, download and share. Article Commentary The Trouble with Doublets: Making Sense of Combination Strategies in Advanced Kidney Cancer
Lara Jr., Primo N. | Pal, Sumanta K. Research Articles A Shared Decision-Making Model for Management of Small Renal Masses: Optimizing the Patient Experience
Caruso, Adele Marie | Ardisson, K. Michelle | Ravishankar, Roshan | Malkowicz, S. Bruce Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy
Verbiest, Annelies | Roussel, Eduard | Tosco, Lorenzo | Joniau, Steven | Laenen, Annouschka | Clement, Paul | Wozniak, Agnieszka | Albersen, Maarten | Beuselinck, Benoit Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma
Lawrence, Nicola J. | Martin, Andrew | Davis, Ian D. | Troon, Simon | Sengupta, Shomik | Hovey, Elizabeth | Coskinas, Xanthi | Kaplan, Richard | Smith, Benjamin | Ritchie, Alastair W. S. | et al. Systematic Review Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review
Schmidt, Andrew L. | Bain, Paul A. | McGregor, Bradley A. Other Clinical Trials Corner: Healthy Competition
Parikh, Mamta | Most Viewed Kidney Cancer Articles in December 2020 Listing research/review articles published in 2020 so you can read the most popular recent content Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review (Systematic Review, Vol.4, Iss.4, 2020)
Schmidt, Andrew L. | Bain, Paul A. | McGregor, Bradley A. Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies (Research Article in Vol.4, Iss.3, 2020)
Dizman, Nazli | Salgia, Nicholas J. | Bergerot, Paulo G. | Hsu, JoAnn | Ruel, Nora | Pal, Sumanta K. Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review (Systematic Review in Vol.4, Iss.2, 2020)
Jang, Albert | Chen, Shuang R. | Xie, John | Bilen, Mehmet A. | Barata, Pedro C. The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice (Review Article in Vol.4, Iss.3, 2020)
Huang, Jennifer J. | Hsieh, James J. Comparing the Responses of Osseous Versus Soft-Tissue Metastases of Renal Cell Carcinoma to Receptor Tyrosine Kinase Inhibitors and Immunotherapy (Research Article in Vol.4, Iss.3, 2020)
Tai, Katherine Yuxi | El Abiad, Jad M. | Morris, Carol D. | Markowski, Mark Christopher | Levin, A.S. Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib (Research Article in Vol.4, Iss.3, 2020)
Beuselinck, Benoit | Van Brussel, Thomas | Verbiest, Annelies | Vanmechelen, Maxime | Couchy, Gabrielle | Oudard, Stéphane | Elaïdi, Reza | Roussel, Eduard | Albersen, Maarten | et al. | Kidney Cancer Association News The Kidney Cancer Association is proud to offer the following free continuing medical education (CME) sessions to healthcare professionals interested in advancing their clinical knowledge in kidney cancer. These activities take the form of a Virtual Tumor Board and Lecture Series. Full details are available on the website here. Interactive Tumor Board:
Contemporary Topics in Renal Cell Carcinoma
Review challenging cases which highlight clinical characteristics in locally advanced metastatic clear cell RCC (ccRCC) that help direct systemic therapy. This tumor board is presented by Drs. Christopher Wood, Robert Figlin, Brad Leibovich, Sumanta (Monty) Pal, and Brian Rini. Virtual Lecture Series:
Management of Rare Histologies of Renal Cell Carcinoma. What’s Been Tried, What Works, What Doesn’t Work, and What We Are Working On – Presented by Pavlos Msaouel, MD, PhD Is There Still a Role For Cytoreductive Nephrectomy in the Setting of Metastatic Disease for Renal Cell Carcinoma in 2020? – Presented by Axel Bex, MD, PhD Salvage Therapies for Metastatic Renal Cell Carcinoma – Presented by Toni Choueiri, MD Palliative Care for mRCC – Presented by Sumanta K. Pal, MD View the CME programming via the website here | Please Share Kidney Cancer News With Your Colleagues Help Spread the News! | If you know of any colleagues or fellow researchers who are not yet signed up to receive the newsletter, we invite you to share this mailing with them. Click on the visual or access the sign-up link here. Kidney Cancer has an active social media presence. If you are not yet interacting with the journal on social media, why not take the time today to follow us on Twitter? Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from KCA.
You can unsubscibe or alter your preferences at any time by clicking the links below. | |
